Analystreport

Atrinsic (NASDAQ:PTIX) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.

Protagenic Therapeutics, Inc.  (PTIX) 
US:NASDAQ Investor Relations: protagenic.com/investors